Table 4 Tepotinib safety overview in NSCLC patients with METex14 skipping mutation (VISION Tepotinib trial)
From: Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
Adverse events-N (%) | All grades | Grade 1 or 2 | Grade 3 |
|---|---|---|---|
Any | 135 (89) | 93 (61) | 38 (25) |
Peripheral edema | 96 (63) | 85 (56) | 11 (7) |
Nausea | 39 (63) | 38 (25) | 1 (1) |
Diarrhea | 33 (22) | 32 (21) | 1 (1) |
Creatinine increased | 27 (18) | 26 (17) | 1 (1) |
Hypoalbuminemia | 24 (16) | 21 (14) | 3 (2) |
Amylase increased | 17 (11) | 13 (9) | 3 (2) |
Lipase increased | 13 (9) | 9 (6) | 4 (3) |
Asthenia | 12 (8) | 11 (7) | 1 (1) |
Decreased appetite | 12 (8) | 11 (7) | 1 (1) |
Pleural effusion | 12 (8) | 8 (5) | 4 (3) |
Alopecia | 12 (8) | 12 (8) | 0 |
Fatigue | 11 (7) | 10 (7) | 1 (1) |
ALT increased | 11 (7) | 7 (5) | 3 (2) |
AST increased | 10 (7) | 7 (5) | 2 (1) |
Vomiting | 9 (6) | 9 (6) | 0 |
General edema | 9 (6) | 5 (3) | 0 |
Upper abdominal pain | 8 (5) | 8 (5) | 0 |